Quick Hits

When we think about the optimal approach to managing patients with eosinophilic esophagitis (EoE), an important question arises: what is the most meaningful endpoint for therapy in EoE — is it histologic remission, endoscopic improvement or symptomatic resolution? While there may be some controversy among investigators regarding which endpoint is most important, most will agree […]

Quick Hits

Much progress has been made since the first studies of pancreatic screening were published almost 20 years ago. We have a better understanding of the risk factors that define high-risk individuals, and we have begun to understand the benefits and risks of pancreatic screening using endoscopic ultrasound (EUS) and other imaging tests. However, we have […]

Quick Hits

As gastroenterologists, we are understandably concerned with cuts in reimbursement, time pressures on clinic visits and other financial metrics that may set us back. Such issues often guide physicians’ stances on health reform, and it is easy to feel overwhelmed. However, as the health care debate continues, we should also remember that we have a […]

Quick Hits

The four U.S. gastroenterology and hepatology societies have made history this year. For the first time, the presidents of AGA, AASLD, ACG and ASGE are women. To mark and celebrate this occasion, the four presidents shared their experience and advice on taking on a leadership position. Sheila E. Crowe MD, AGAF AGA President What motivated you […]

Quick Hits

Combination direct-acting antiviral (DAA) therapy of eight to 24 weeks for the treatment of chronic hepatitis C is highly effective. Current guidelines do not encourage treatment for less than 12 weeks. However, mounting evidence indicates that many patients can achieve sustained virologic response (SVR) with only eight weeks of treatment. Thus, treatment for shorter durations […]

Quick Hits

Acute alcoholic hepatitis is a clinical syndrome characterized by sudden onset of jaundice, malaise, anorexia and occasionally abdominal pain associated with fever, tachycardia, leukocytosis and other evidence of a systemic inflammatory response in an individual who has been drinking heavily within the preceding eight weeks. By definition, serum bilirubin is elevated with modest elevation in […]

Quick Hits

With the recent approvals of infliximab biosimilars, CT-P13 and SB2, and adalimumab biosimilar, ABP 501, by the U.S. FDA, the landscape of available anti-tumor necrosis factor (TNF) therapies for the treatment of inflammatory bowel disease (IBD) is changing right before our eyes. To understand the implications of this change, it is important to consider several […]

Quick Hits

One of the most common clinical challenges that endoscopists encounter is how to properly manage antithrombotic agents in patients undergoing endoscopic procedures. Optimal management requires strategies individualized to specific patients. Physicians must consider the bleeding risk of the endoscopic procedure being performed, the underlying patient condition necessitating the antithrombotic therapy and the specific characteristics of […]

Quick Hits

The advent of direct acting antivirals (DAAs) in the treatment of chronic hepatitis C infection has been revolutionary in that they have drastically mitigated the side effects of therapy while enhancing efficacy relative to interferon-based therapy. DAAs are broadly categorized into the NS3/4A protease inhibitors, NS5A inhibitors, and the non-nucleoside and nucleotide NS5B inhibitors. Ribavirin, […]

Quick Hits

This commentary describes the current status of the multi-target stool DNA test (mt-sDNA) (Cologuard®, Exact Sciences, Madison, WI) and of stool-based markers for GI diseases. Approved by both the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services in August 2014, the mt-sDNA test is a non-invasive screening test for colorectal […]